How is the Viral Vectors And Plasmid DNA Manufacturing Market Poised for Growth: Trends and Opportunities Through 2034
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What is the Predicted CAGR for the Viral Vectors And Plasmid DNA Manufacturing Market Over the Forecast Period of 2025 to 2034?
In recent times, there has been an exponential growth in the market size of viral vectors and plasmid DNA manufacturing. This market is projected to increase from $5.75 billion in 2024 to $7.11 billion in 2025, with a compound annual growth rate (CAGR) of 23.8%. Factors like the demand for customised medicine, surge in vaccine development, sufficient funding for gene therapy development, efficiency of viral vectors in delivering gene therapy, and their potential use in innovative drug delivery methods are driving the growth of this market during the historic period.
Anticipated to experience a substantial growth spurt in the upcoming years, the market for viral vectors and plasmid DNA manufacturing is predicted to expand to a whopping $16.52 billion by 2029, growing at a compound annual growth rate (CAGR) of 23.5%. The considerable growth during the forecast duration could be attributed to various factors, including a rise in gene therapies, the increased count of market participants, a surge in infectious illness rates and genetic anomalies, higher influx of investments in the research domain of cell and gene therapies, and an escalating prevalence of specific disorders and diseases. The incoming period is also expected to witness key trends such as innovations in technology, advancements in gene therapy, adoption of cutting-edge technologies, embracing single-use technologies, along with progress in vaccine technology.
What Factors Are Propelling the Growth of the Viral Vectors And Plasmid DNA Manufacturing Market from 2025 to 2034?
The upward trend in the number of gene therapies is poised to catalyze the expansion of the viral vectors and plasmid DNA manufacturing market in the future. Gene therapy is a treatment technique that manipulates, adds, or eliminates genetic material within a person’s cells to manage or prevent diseases. The progression of gene therapy is crucial, given the escalation in research and development investments in biotechnology and an improved knowledge of the genetic and cellular processes crucial to a range of diseases. Viral vectors and plasmid DNA manufacturing make it possible to deliver curative genes into the cells of the patient, thereby treating genetic diseases at the molecular level. For example, the American Society of Gene & Cell Therapy, a non-profit organization based in the United States focusing on medical and scientific research, reported a 10% rise in the number of gene therapies undergoing Phase III clinical trials in Q3 2023, marking the first quarterly surge since Q3 2022. Consequently, the escalating count of gene therapies fuels the growth of the viral vectors and plasmid DNA manufacturing market.
Explore Comprehensive Insights Into The Global Viral Vectors And Plasmid DNA Manufacturing Market With A Free Sample Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20690&type=smp
Who Are the Top Companies Driving Innovation and Growth in the Viral Vectors And Plasmid DNA Manufacturing Market?
Major companies operating in the viral vectors and plasmid DNA manufacturing market are:
• Merck KGaA
• Thermo Fisher Scientific Inc.
• Astellas Pharma Inc.
• Lonza Group AG
• Catalent Inc.
What Key Trends Are Currently Impacting the Viral Vectors And Plasmid DNA Manufacturing Market’s Development?
Leading companies in the viral vectors and plasmid DNA manufacturing market are focusing on strategic alliances to grow their production capacities, improve their technological prowess, and hasten gene therapies’ global development and commercialization. These partnerships allow firms to pool resources and infrastructure, thereby augmenting overall manufacturing capacity to cater to the rising need for gene therapies. For example, in June 2024, US-based Charles River Laboratories International Inc., a preclinical and clinical contract research group, and Captain T Cell, a spinoff of the famed Max Delbrück Center Berlin in Germany, initiated a plasmid DNA and retrovirus vector production program agreement. The partnership offers Captain T Cell access to established contract development and manufacturing (CDMO) capacities and consulting services. Moreover, it is designed to speed up the passage from preclinical research to clinical trials for a novel TCR-T cell therapy targeting solid tumors.
Secure Your Global Viral Vectors And Plasmid DNA Manufacturing Market Report Now for Fast and Efficient Delivery!
Which Segments Play a Crucial Role in the Expansion of the Viral Vectors And Plasmid DNA Manufacturing Market?
The viral vectors and plasmid dna manufacturing market covered in this report is segmented –
1) By Product Type: Plasmid Deoxyribonucleic Acid (DNA), Viral Vector, Non-Viral Vector
2) By Scale Of Operation: Preclinical, Clinical, Commercial
3) By Therapeutic Area: Oncological Disorders, Rare Diseases, Neurological Disorders, Sensory Disorders, Metabolic Disorders, Musculoskeletal Disorders, Blood Disorders, Immunological Disorders, Other Disorders
4) By Application Area: Gene Therapies, Cell Therapies, Vaccines
5) By Type Of Manufacturer: In-house Manufacturers, Contract Manufacturing Organizations
Subsegments:
1) By Plasmid Deoxyribonucleic Acid (DNA): Linear Plasmid DNA, Circular Plasmid DNA, High-Copy Plasmid DNA, Low-Copy Plasmid DNA
2) By Viral Vector: Adenoviral Vectors, Lentiviral Vectors, Adeno-Associated Viral Vectors (AAV), Retroviral Vectors
3) By Non-Viral Vector: Liposome-Based Vectors, Polymer-Based Vectors, Nanoparticle-Based Vectors, Electroporation-Based Vectors
Which Geographical Regions Are Pioneering Growth in the Viral Vectors And Plasmid DNA Manufacturing Market?
North America was the largest region in the viral vectors and plasmid DNA manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral vectors and plasmid DNA manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Do Experts Define the Scope of the Viral Vectors And Plasmid DNA Manufacturing Market?
Viral vectors and plasmid DNA manufacturing refers to the production processes involved in creating viral vectors and plasmid DNA, which are essential tools in gene therapy, vaccine development, and genetic research. The manufacturing of these components involves complex biotechnological processes to ensure the safety, efficacy, and consistency of the final products.
Browse Through More Similar Reports By The Business Research Company:
Viral Vectors & Plasmid DNA Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/viral-vectors-and-plasmid-dna-global-market-report
Bacterial And Plasmid Vectors Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/bacterial-and-plasmid-vector-global-market-report
Prenatal DNA Sequencing Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/prenatal-dna-sequencing-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: